Guggenheim initiated coverage on shares of Immunome (NASDAQ:IMNM – Free Report) in a report issued on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $35.00 target price on the stock. Several other equities analysts have also issued reports on IMNM. Wedbush boosted their price target on Immunome from $27.00 to […]